Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004699-31
    Sponsor's Protocol Code Number:I3O-MC-JSBF
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-05-19
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-004699-31
    A.3Full title of the trial
    Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
    Estudio de fase 2, aleatorizado, doble ciego, en el que se evalúa la administración de ramucirumab o merestinib o placebo con cisplatino y gemcitabina como tratamiento de primera línea en pacientes con cáncer de las vías biliares metastásico o en estadío avanzado
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study investigates whether ramucirumab or merestinib in combination with cisplatin and gemcitabine can help patients with biliary tract cancer.
    El estudoi investiga si ramucirumab o merestinib en combinación con cisplatino y gemcitabina puede ayudar a los pacientes con cancer de las vías biliares
    A.4.1Sponsor's protocol code numberI3O-MC-JSBF
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLilly, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEli Lilly and Company
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLilly, S.A.
    B.5.2Functional name of contact pointGemma Méndez
    B.5.3 Address:
    B.5.3.1Street AddressAvenida de la Industria, 30
    B.5.3.2Town/ cityAlcobendas
    B.5.3.3Post code28108
    B.5.3.4CountrySpain
    B.5.4Telephone number+34 916635252
    B.5.5Fax number+34 916633481
    B.5.6E-mailensayosclinicos@lilly.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cyramza
    D.2.1.1.2Name of the Marketing Authorisation holderEli Lilly Nederland B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRamucirumab
    D.3.9.1CAS number 947687-13-0
    D.3.9.3Other descriptive nameRAMUCIRUMAB
    D.3.9.4EV Substance CodeSUB32795
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMerestinib
    D.3.2Product code LY2801653
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMerestinib
    D.3.9.3Other descriptive nameMERESTINIB
    D.3.9.4EV Substance CodeSUB180030
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced or Metastatic Biliary Tract Cancer
    Cancer de vías biliares avanzado o metastásico
    E.1.1.1Medical condition in easily understood language
    Advanced or Metastatic Biliary Tract Cancer
    Cancer de vías biliares avanzado o metastásico
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the efficacy, in terms of PFS, in patients with advanced or metastatic BTC, for
    ? ramucirumab (8 mg/kg, IV) versus placebo, in combination with cisplatin (25 mg/m2, IV) and gemcitabine (1000 mg/m2, IV), on Days 1 and 8 of a 21-day cycle.
    ? merestinib (80 mg, oral each day) versus placebo, in combination with cisplatin (25 mg/m2, IV) and gemcitabine (1000 mg/m2 IV), on Days 1 and 8 of a 21-day cycle.
    Evaluar la eficacia, desde el punto de vista de la SSP, en pacientes con CVB metastásico o en estadio avanzado, de:
    ?Ramucirumab (8 mg/kg, i.v.) frente al placebo, en politerapia con cisplatino (25 mg/m2, i.v.) y gemcitabina (1000 mg/m2, i.v.), los días 1 y 8 de cada ciclo de 21 días.
    ?Merestinib (80 mg, por vía oral, todos los días) frente al placebo, en politerapia con cisplatino (25 mg/m2, i.v.) y gemcitabina (1000 mg/m2, i.v.), los días 1 y 8 de cada ciclo de 21 días.
    E.2.2Secondary objectives of the trial
    - Evaluate the efficacy, in combination with cisplatin and gemcitabine, in terms of OS, for ramucirumab versus placebo and merestinib versus placebo.
    - Evaluate the efficacy, in combination with cisplatin and gemcitabine, in terms of ORR and DCR for ramucirumab versus placebo and merestinib versus placebo.
    - Safety profile of merestinib
    - Safety profile of ramucirumab
    - PK of ramucirumab
    - PK of merestinib
    - Immunogenicity of ramucirumab
    - Evaluate PRO measures of disease-specific symptoms, in combination with cisplatin and gemcitabine, for ramucirumab versus placebo and merestinib versus placebo.
    - Evaluar la eficacia, desde el punto de vista de la SG y en politerapia con cisplatino y gemcitabina, de ramucirumab frente al placebo y de merestinib frente al placebo.
    - Evaluar la eficacia, desde el punto de vista de la TRO y la TCE y en politerapia con cisplatino y gemcitabina, de ramucirumab frente al placebo y de merestinib frente al placebo.
    - Perfil de seguridad de ramucirumab
    - Perfil de seguridad de merestinib.
    - FC de ramucirumab
    - FC de merestinib
    - Inmunogenicidad de ramucirumab
    - Evaluar los instrumentos de medida de los resultados percibidos por el paciente en lo que respecta a los síntomas específicos de la enfermedad, en politerapia con cisplatino y gemcitabina, de ramucirumab frente al placebo y de merestinib frente al placebo.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    I3O-MC-JSBF(1): Drug- Drug Interaction addendum
    An additional secondary objective for the DDI substudy will be to assess the PK of gemcitabine and cisplatin with and without ramucirumab or merestinib.
    I3O-MC-JSBF(1): Adenda de Interacciones farmacogenéticcas
    Un objetivo secundario adicional del subestudio es la valoración de la FC de gemcitabina y cisplatino con y sin ramucirumab o merestinib.
    E.3Principal inclusion criteria
    [1] Are of an acceptable age to provide informed consent according to the local regulations and are at least 18 years of age.
    [2] Have an estimated life expectancy ?3 months.
    [3] Have an Eastern Cooperative Oncology Group performance status of 0 or 1 at the time of randomization (refer to Appendix 7).
    [4] Have a histologically or cytologically confirmed diagnosis of non-resectable, recurrent, or metastatic biliary tract adenocarcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or Ampulla of Vater).
    [5] Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) assessments performed ? 28 days prior to Cycle 1 Day 1.
    [6] Have resolution of all clinically significant toxic effects of prior therapy to Grade ?1 by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0.
    [7] Have adequate biliary drainage (per investigator?s discretion), with no evidence of ongoing infection.
    [8] Have adequate organ function as determined by:
    a. Hepatic: Total bilirubin, aspartate transaminase (AST), and alanine transaminase (ALT) are all ? 3 times upper limit of institutional normal value (ULN) on 2 measurements separated by at least 5 days.
    b. Renal:
    i. Glomerular filtration rate (GFR) of ?50 ml/min/1.73 m2. GFR should be calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (refer to Appendix 6), or may be measured using 24 hour urine collection or clearance of exogenous filtration markers (such as iothalamate or 51-CrEDTA or Tc99m-DTPA).
    ii. The patient?s urinary protein is ?1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ?2+, then a 24-hour urine must be collected and must demonstrate <2 g of protein in 24 hours to allow participation in the study.
    c. Hematologic:
    i. Absolute neutrophil count (ANC) ?1.5 x 109/L,
    ii. hemoglobin ?9 g/dL (5.58 mmol/L; packed red blood cell transfusions are not allowed within 1 week prior to baseline hematology profile), and
    iii. platelets ? 100 x 109/L.
    d. Coagulation: The patient must have adequate coagulation function as defined by International Normalized Ratio (INR) ?1.5 and a partial thromboplastin time (PTT/aPTT) ?5 seconds above the ULN. Patients receiving low-dose anticoagulant therapy at prophylactic doses (such as prophylaxis with low-molecular weight heparin) are eligible, provided that INR ?1.5 and PTT/aPTT ?5 seconds above the ULN. Treatment with acetylsalicylic acid (aspirin) at a daily dose of ?325 mg is permitted.
    [9] Males and females are sterile, postmenopausal, or compliant with a highly effective contraceptive method during study participation and for 3 months following the last dose of study drug.
    [10] Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose.
    [11] The patient has provided signed informed consent and authorization for release of health information for research prior to any study-specific procedures and is amenable to compliance with protocol schedules and testing.
    [12] Are willing to provide blood/serum/plasma and tumor tissue samples for research purposes. Submission of blood/serum/plasma and tumor tissue samples is mandatory for participation in this study, unless restricted per local regulations. Tumor tissue biopsies may be taken by either core needle or excisional biopsy.
    [13] Are able to swallow tablets. Patients who have a nontemporary gastric or enteral feeding tube may be permitted to participate in the study with prior approval from the Sponsor?s CRP/CRS.
    [1]Edad aceptable para proporcionar el consentimiento informado y tener al menos 18 años.
    [2] esperanza de vida estimada ? 3 meses.
    [3]Presentar en el momento de la aleatorización una categoría funcional del Eastern Cooperative Oncology Group de 0 o 1 (véase el anexo 7).
    [4]diagnóstico confirmado de adenocarcinoma de las vías biliares no resecable, recurrente o metastásico (colangiocarcinoma intrahepático o extrahepático, cáncer de la vesícula biliar o ampolla de Vater).
    [5]enfermedad mensurable, de acuerdo con TAC o RMN ? 28 días antes del día 1 del ciclo1 y los Criterios de evaluación de la respuesta en tumores sólidos (RECIST), versión 1.1.
    [6]Todos los efectos tóxicos clínicamente significativos de los tratamientos anteriores deben haberse resuelto hasta alcanzar un grado ? 1, de acuerdo con los Criterios terminológicos comunes para los acontecimientos adversos del National Cancer Institute (versión 4.0)
    [7] drenaje biliar aceptable, sin signos de infección persistente.
    [8]función orgánica aceptable, según siguientes
    a.Hepáticos: Concentración de bilirrubina total, AST y ALT ? 3 veces el límite superior de la normalidad del centro en 2 mediciones, entre las cuales deben haber transcurrido al menos 5 días.
    b.Renales:
    i.VFG ? 50 ml/min/1,73 m2. La VFG debe calcularse mediante la ecuación de la CKD-EPI, aunque también puede determinarse utilizando una muestra de orina de 24 horas o basándose en el aclaramiento de marcadores de filtración exógenos
    ii.El paciente presenta un valor de proteínas en orina ? 1+, de acuerdo con los resultados de la tira reactiva o de un análisis de orina ordinario. En caso de que los resultados de la tira reactiva o del análisis de orina ordinario indiquen la presencia de proteinuria ? 2+, deberá recogerse una muestra de orina de 24 horas en la que deberá observarse una cantidad de proteínas < 2 g para que el paciente pueda participar en el estudio.
    c.Hematológicos:
    i.Recuento absoluto de neutrófilos (RAN) ? 1,5 × 109/l.
    ii.Hemoglobina ? 9 g/dl o (5,58 mmol/l; no se permiten transfusiones de unidades de concentrados de eritrocitos en el transcurso de la semana previa a la determinación del perfil hematológico basal), y
    iii.Número de plaquetas ? 100 × 109/l.
    d.Coagulación: El paciente debe presentar una coagulación aceptable, esto es, un índice internacional normalizado ? 1,5 y un TTP/TTPa ? 5 segundos por encima del LSN. Los pacientes que estén recibiendo tratamiento anticoagulante en dosis bajas, por ejemplo, heparina de bajo peso molecular, se considerarán idóneos si el INR es ? 1,5 y el TTP/TTPa ? 5 segundos por encima del LSN. Se permite la administración de ácido acetilsalicílico en una dosis diaria ? 325 mg.
    [9]Los pacientes (de ambos sexos) deben ser estériles, haber entrado en la posmenopausia (en el caso de mujeres) o utilizar un método anticonceptivo muy eficaz durante la participación en el estudio y los 3 meses posteriores a la última dosis del fármaco del estudio.
    [10]Las mujeres potencialmente fértiles deben presentar un resultado negativo en una prueba de embarazo en suero que deberá realizarse en el transcurso de los 7 días previos a la primera dosis.
    [11]El paciente debe haber proporcionado el consentimiento informado firmado y una autorización para la divulgación de información relativa a su salud con fines de investigación, antes de que se lleve a cabo cualquiera de los procedimientos específicos del estudio, y debe estar dispuesto a cumplir el calendario y las pruebas del protocolo.
    [12]Estar dispuesto a proporcionar muestras de sangre/suero/plasma y tejido tumoral con fines de investigación. Para participar en este estudio es obligatorio proporcionar muestras de sangre/suero/plasma y tejido tumoral, a menos que exista alguna restricción de acuerdo con la normativa local. Las biopsias del tejido tumoral podrán realizarse mediante biopsia con aguja gruesa o biopsia excisional.
    En caso de que se disponga de una muestra suficiente de tejido tumoral del paciente procedente de una biopsia previa realizada en el transcurso de los 28 días anteriores, podrá presentarse este material antes que realizar otra biopsia.
    En caso de que el tejido tumoral disponible se limite a una citología obtenida mediante cepillado citológico, se podrá considerar que el paciente es idóneo para participar en el estudio si el médico de investigación clínica (CRP)/el científico de investigación clínica (CRS) lo aprueba, tras haberlo comentado con el investigador.
    En caso de que el paciente realice de nuevo el proceso de selección y se disponga de tejido tumoral aceptable que se hubiera obtenido en el proceso de selección anterior, deberá contarse con la aprobación del CRP/CRS de Lilly para que no se realice una biopsia nueva al paciente.
    [13]Ser capaz de ingerir comprimidos. Los pacientes con una sonda nasogástrica que no sea temporal podrán participar en el estudio si el CRP/CRS del promotor lo aprueba.
    E.4Principal exclusion criteria
    [14] Previous systemic therapy for locally advanced or metastatic disease is not allowed. Transarterial chemoembolization (TACE) or radiotherapy, including use of radioactive beads, is not allowed unless otherwise addressed in the Exclusion Criterion 18. See protocol for previous allowed treatments:
    [15] Have a history of or have current hepatic encephalopathy of any grade, or ascites of Grade >1, or cirrhosis with Child-Pugh Stage B or higher.
    [16] Have ongoing or recent (?6 months) hepatorenal syndrome
    [17] Have had a major surgical procedure or significant traumatic injury including non-healing wound, peptic ulcer, or bone fracture ?28 days prior to randomization, or anticipate having a major surgical procedure during the course of the study. Randomization should only occur after complete wound healing. Subcutaneous venous access device placement should not be considered a significant surgery, but should be placed greater than 7 days prior to randomization.
    [18] Have had radiation to any site (for example, bone) within 14 days prior to randomization. Palliative radiation to symptomatic metastatic sites (for example, bone) is permitted, provided it is performed >14 days prior to randomization. If any tumor lesion is administered radiotherapy, then it cannot be considered for response assessment.
    [19] Has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression. Screening of asymptomatic patients without history of central nervous system (CNS) metastases is not required. However, patients with findings consistent with CNS malignancy or metastasis should be evaluated fully before study participation.
    [20] Have had any previous systemic therapy with VEGF inhibitors or VEGF-Receptor inhibitors (including investigational agents).
    [21] Are receiving therapeutic dose anticoagulation with warfarin, low-molecular-weight heparin, or similar agents (see also Inclusion Criterion 8d).
    [22] Are receiving chronic therapy with nonsteroidal anti-inflammatory agents (NSAIDs: for example, indomethacin, ibuprofen, naproxen, or similar agents) or other anti-platelet agents (for example, clopidogrel, ticlopidine, dipyridamole, anagrelide). Aspirin use at doses up to 325 mg/day is permitted
    [23] Symptomatic congestive heart failure (New York Heart Association III-IV are excluded, Class I and II are eligible), unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia.
    [24] Within 6 months prior to randomization, have had any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.
    [25] Have an uncontrolled arterial hypertension with systolic blood pressure ?150 or diastolic blood pressure ?90 mm Hg despite standard medical management.
    [26] Have a previous malignancy within 5 years of study entry or a concurrent malignancy. Patients with carcinoma in situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low, as judged by the Lilly CRP/CRS in consultation with the treating investigator, are eligible for this study. The approval by the CRP/CRS of such patients is required before these patients may be enrolled.
    [28] Have a history of gastrointestinal perforation and/or fistulae within 6 months prior to randomization.
    [29] Have a known allergy or hypersensitivity reaction to any of the treatment components.
    [30] Have a history of uncontrolled hereditary or acquired thrombotic disorder.
    [31] Have uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient ineligible for entry into this study.
    [32] Have mixed hepatocellular biliary tract cancer histology.
    [33] Females who are pregnant or lactating.
    [34] Have a QTc interval >470 msec as calculated be the Fredericia equation.
    [35] The patient experienced any bleeding episode considered life-threatening, or any Grade 3 or 4 gastrointestinal/variceal bleeding episode in the 3 months prior to randomization requiring transfusion or endoscopic or operative intervention
    [15] antecedentes o experimentar en la actualidad encefalopatía hepática de cualquier grado, ascitis de grado > 1 o cirrosis de clase B de Child-Pugh o peor grado.
    [16] Presentar en la actualidad o haber presentado recientemente (? 6 meses) síndrome hepatorrenal.
    [17] Haberse sometido a un procedimiento quirúrgico mayor o haber sufrido un traumatismo significativo (herida o una úlcera gastroduodenal que no haya cicatrizado o una fractura ósea no consolidada ? 28 días antes de la aleatorización, o previsión de procedimiento quirúrgico mayor durante el estudio. La aleatorización debe realizarse solo una vez que la herida haya cicatrizado completamente. La colocación de un dispositivo de acceso venoso subcutáneo no se considera intervención quirúrgica significativa, pero debe colocarse más de 7 días antes de la aleatorización.
    [18] Radioterapia en los 14 días anteriores a la aleatorización. Se permite radioterapia paliativa en las metástasis sintomáticas, si se ha administrado > 14 días antes de la aleatorización.
    [19] metástasis cerebrales, enfermedad leptomeníngea o compresión medular no controlada. Los pacientes con signos de presencia de neoplasias malignas o metástasis en SNC deben someterse a evaluación completa antes de la participación en el estudio.
    [20] Cualquier tratamiento sistémico previo con inhibidores del VEGF o de receptores del VEGF.
    [21] Estar recibiendotratamiento anticoagulante con dosis terapéuticas de warfarina, heparina de bajo peso molecular o fármacos similares.
    [22] Estar recibiendo tratamiento prolongado con AINEs u otros antiagregantes plaquetarios . Se permite la administración de dosis de hasta 325 mg/día de ácido acetilsalicílico.
    [23] Presentar insuficiencia cardiaca congestiva sintomática (se excluye a los pacientes que presenten clases III-IV, de acuerdo con los criterios de la New York Heart Association; los pacientes con clase I y II se consideran idóneos para participar en el estudio), angina de pecho inestable o arritmia cardiaca sintomática o mal controlada.
    [24] Haber experimentado cualquier episodio tromboembólico arterial, entre otros, infarto de miocardio, angina de pecho inestable, accidente cerebrovascular o accidente isquémico transitorio, en el transcurso de los 6 meses anteriores a la aleatorización.
    [25] Presentar hipertensión arterial sin controlar, con una tensión arterial sistólica ? 150 mm Hg o una tensión arterial diastólica ? 90 mm Hg, a pesar de recibir el tratamiento farmacológico habitual.
    [26] Haber experimentado una neoplasia maligna en los 5 años anteriores a la inclusión o presentarla actualidad. Podrán participar en este estudio los pacientes con carcinoma in situ de cualquier origen y los que anteriormente hayan experimentado otras neoplasias malignas, estén en remisión y presenten una probabilidad de recurrencia muy baja.
    [27] Estar participando en la actualidad o haber dejado de participar en los últimos 28 días en un ensayo clínico con un producto en fase de investigación o se haga un uso de un fármaco o producto sanitario (salvo los fármacos del estudio que se utilicen en este ensayo) no recogido en su ficha técnica, o estar participando e en cualquier otro ensayo clínico en el que se investigue un producto en fase de investigación o en cualquier otro tipo de investigación médica que se considere que no es compatible con el estudio, desde un punto de vista científico o médico.
    [28] Presentar antecedentes de perforación o fístula gastrointestinal (o de ambas) en los 6 meses anteriores a la aleatorización.
    [29] Presentar alergia o reacción de hipersensibilidad a cualquiera de los componentes del tratamiento.
    [30] Tener antecedentes de trastornos trombóticos sin controlar.
    [31] Presentar trastornos metabólicos sin controlar u otras enfermedades orgánicas o sistémicas no cancerosas, o efectos secundarios del cáncer que se asocien con un riesgo médico alto o que hagan que la evaluación de la supervivencia sea incierta. Cualquier otro trastorno médico o psiquiátrico agudo o crónico y grave, o cualquier alteración analítica que pueda aumentar el riesgo asociado con la participación en el estudio o con la administración del fármaco del estudio, o que pueda interferir en la interpretación de los resultados del estudio y que, en opinión del investigador, haga que el paciente no se considere idóneo para su inclusión en este estudio.
    [32] Presentar cáncer hepatocelular de las vías biliares de histología mixta.
    [33] Mujeres embarazadas o que se encuentren en el período de lactancia.
    [34] Presentar un intervalo QTc > 470 ms, de acuerdo con la fórmula de Fridericia.
    [35] Haber experimentado cualquier episodio hemorrágico potencialmente mortal, o cualquier episodio de hemorragia digestiva por rotura de varices esofágicas/ hemorragia gastrointestinal de grado 3 o 4 en el transcurso de los 3 meses anteriores a la aleatorización, que haya requerido una transfusión o una intervención endoscópica o quirúrgica.
    E.5 End points
    E.5.1Primary end point(s)
    PFS (objective progression or death), as determined by investigator assessment per RECIST 1.1
    SSP (progresión objetiva o muerte), de acuerdo con la evaluación del investigador según los criterios RECIST 1.1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    From randomization until the first radiographic documentation of progression or death from any cause in the absence of progressive disease
    Desde la aleatorización hasta la primera documentación radiográfica de progression de o muerte por cualquier causa en ausencia de progression de la enfermedad
    E.5.2Secondary end point(s)
    OS
    ORR and DCR
    The safety endpoints evaluated will include but are not limited to the following:
    ? TEAEs, AESIs, SAEs, and hospitalizations
    ? Clinical laboratory tests, vital signs, and physical examinations
    ? Minimum ramucirumab concentration in serum
    ? Postdose merestinib concentration in plasma
    Blood samples for immunogenicity testing will be collected to determine antibody production against ramucirumab.
    Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire (FACT-Hep)
    EuroQol 5-Dimension 5-Level (EQ-5D-5L)
    SG
    TRO y TCE
    Entre los criterios de valoración de la seguridad que se evaluarán se incluyen:
    ? AAST, AAIE, AAG y hospitalizaciones.
    ? Análisis clínicos, constantes vitales y exploraciones físicas.
    ? Concentración sérica mínima de ramucirumab
    ? Concentración plasmática de merestinib posterior a la administración de la dosis.
    Se recogerán muestras de sangre para realizar pruebas de inmunogenicidad, esto es, para determinar la presencia de anticuerpos frente a ramucirumab.
    Cuestionario de evaluación funcional del tratamiento antineoplásico ? hepatobiliar (FACT-Hep)
    Cuestionario EuroQol 5 dimensiones y 5 niveles (EQ-5D-5L)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Time period for OS is from randomization until death from any cause.
    For ORR/DCR from randomization until the first radiographic documentation of progression or death from any cause in the absence of progressive disease
    El periodo de tiempo para SG se cuenta desde la aleatorización hasta fallecimiento por cualquier causa
    para ORR and DCR, desde la aleatorización hasta primera documentación radiográfica de progression de la enfermedad o fallecimiento por cualquier causa
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA47
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Belgium
    Czech Republic
    Denmark
    France
    Germany
    Hungary
    Italy
    Korea, Republic of
    Mexico
    Russian Federation
    Spain
    Sweden
    Taiwan
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita del ultimo paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days5
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 225
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 75
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 147
    F.4.2.2In the whole clinical trial 364
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who are still on study treatment at the time of study completion may continue to receive study treatment if they are experiencing clinical benefit and no undue risks. Placebo will no longer be administered, and crossover will not be permitted.
    Los pacientes que continuen en tratamiento en el momento de finalizar el studio pueden continuar recibiendo la medicación de estudio si experimentan beneficio clinic y sin riesgos no esperados. El placebo no se seguirá administrando y no se permitirá cruce de tratamiento
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-05-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-03-17
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 23:12:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA